AI assistant
Oramed Pharmaceuticals Inc. — Director's Dealing 2021
Dec 7, 2021
6965_dirs_2021-12-07_f50e796f-1d58-4588-84c6-70fc8a515cf2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2021-08-09
Reporting Person: KIDRON NADAV (Director, President and CEO, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-09 | Common Stock | S | 220000 | $20.1052 | Disposed | 738209 | Direct |
Footnotes
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 18, 2021.
F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 18, 2021.
F3: This amendment is being filed to correct an administrative error in Form 4 filed by Mr. Kidron, which reported that 648,573 shares of common stock are beneficially owned by him following the reported transaction. Mr. Kidron beneficially owned 738,209 shares of common stock following the reported transaction.